Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

regimen

DEXAIMATVNCR

Cancer Type
Hematologic, Leukemia - Acute Lymphoblastic (ALL)
Intent
Curative
Regimen Category
evidence-informed
Funding Program
ODB - General Benefit iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®

Regimen Monograph

Apr 2024

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

Last Updated: July 21, 2026